Pharma Leaders Eli Lilly and Merck Offer Durable Dividend Opportunities

Two standout dividend stocks to consider for long-term investment are Eli Lilly and Merck. Both companies have impressive financial results, driven by their innovative products in the pharmaceutical industry.

Eli Lilly's Mounjaro and Zepbound have been top performers, with revenue increasing 48% year-over-year to $23 billion in the second quarter. The company's adjusted earnings per share climbed 33% to $8.38. Eli Lilly's pipeline includes promising candidates like retatrutide and eloralintide, which could expand its market lead.

Merck's Keytruda, a cancer medicine, will lose patent exclusivity in the U.S. in 2028, but the company has several products in development to replace it. Keytruda Qlex, a subcutaneous version of the original formulation, is expected to retain patients and contribute to revenue growth.

Both companies have strong dividend programs, with Eli Lilly's forward yield at 0.6% and Merck's at 2.3%. Merck has increased its payouts by almost 90% over the past decade.